ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
|Articles|December 9, 2020
AstraZeneca and HALIX Team Up for COVID-19 Vaccine Manufacturing
Author(s)BioPharm International Editors
CDMO HALIX will manufacture the drug substance for AstraZeneca’s COVID-19 vaccine candidate, AZD1222, at commercial scale at its cGMP facility in the Netherlands.
Advertisement
AstraZeneca announced on Dec. 8, 2020 that it has signed an agreement with HALIX, a biopharmaceutical contract development and manufacturing organization, for the large-scale commercial drug substance manufacturing of its vector-based COVID-19 vaccine, AZD1222.
Under the terms of the agreement, HALIX will handle the commercial manufacturing of the drug substance at its current good manufacturing practice (cGMP) facility at the Leiden Bio Science Park in the Netherlands, HALIX said in a company press release. HALIX will also continue its role as one of the original partners in the University of Oxford’s consortium for the manufacturing of the vaccine through the agreement.
“Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca,” said Alex Huybens, chief operations officer, HALIX, in the press release. “Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis.”
Source:
Advertisement
Related to this article
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.
argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5